Sisram Medical Ltd (HKG:1696) said it plans to enter into new one-year sublicensing and promotional services contracts with Fosun Wanbang (Jiangsu) capped at $15 million, according to a Monday bourse filing.
The company said its similar previous contracts will expire at the end of the year and the new contracts, if approved by the board at a special meeting, will run through 2027.
Shares were last down 2% in Tuesday afternoon trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.